Trump announces deal to lower weight loss drug prices in some cases
The deal, with Eli Lilly and Novo Nordisk, is expected to lower the price of obesity drugs to between $149 and $350 per month in some cases, officials said.
Watch CBS News
The deal, with Eli Lilly and Novo Nordisk, is expected to lower the price of obesity drugs to between $149 and $350 per month in some cases, officials said.
Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.
The FDA says the nationwide shortage for Ozempic and Wegovy is over, but as CBS News New York's Ali Bauman explains, that supply change could lead to consumers paying more.
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.
Health experts say popular weight-loss drugs like Ozempic and Wegovy are safe, but the FDA warns counterfeits are becoming more widespread.
Health experts say popular weight-loss drugs like Ozempic and Wegovy are safe, but the FDA warns counterfeits are becoming more widespread. CBS News New York's Lisa Rozner reports.
Millions of Americans have turned to popular prescription medications to treat diabetes and lose weight, but some say the drugs can have serious negative health effects. CBS News senior investigative consumer correspondent Anna Werner has been looking into this.
Do weight loss drug labels warn enough about potential side effects? A patient who needed emergency surgery is suing prescription drugmaker Novo Nordisk.
Dr. Jayne Morgan joins CBS New York to discuss how GLP-1 medications like Ozempic can prevent cancer.
CBS New York's Jessica Moore looks into the widespread impact of these life-changing medications.
Isis Navarro Reyes, of New York, allegedly posted TikTok videos marketing weight loss drugs that appeared to be Ozempic, Mesofrance and Axcion.
Prosecutors say Isis Navarro Reyes posted social media videos marketing drugs that appeared to be Ozempic, Mesofrance and Axcion.
Diabetes drugs like Ozempic have gained popularity for weight loss, but a New York City Council member is hoping to raise more awareness about side effects with a new bill.
Diabetes drugs like Ozempic have gained popularity for weight loss, but a New York City Councilmember is hoping to raise more awareness about side effects with a new bill. She told CBS New York's Jenna DeAngelis she's also been inundated with complaints from diabetes patients unable to access their life-saving meds.
Many people looking to lose weight are turning to Ozempic and similar drugs. The issue is that those medicines are also used by people with diabetes.
Many people looking to lose weight are turning to Ozempic and similar drugs. The issue is that those medicines are also used by people with diabetes. CBS New York's Lisa Rozner reports.
GLP-1 class medications reduce cardiovascular risk and treat diabetes. But they also allow people to lose an average of 10-20 percent of their body weight in the first year. What does that mean for the overweight or obese?
Ozempic and other GLP-1 class medications are being proven beneficial for reducing cardiovascular risk and treating diabetes. But they also signal fullness to the brain and regulate blood sugar, allowing people to lose on average 10 to 20 percent of their body weight in the first year. For many of the roughly 74 percent of Americans who are overweight or obese, that's almost unimaginable. Correspondent Susan Spencer talks with doctors and patients about how these drugs work, and why they are considered life-changing (and even, for Wall Street analysts, a miracle).
How do you know what weight loss method is right for you, and what is the safest way to get it accomplished? We ask the director of the Center for Weight Loss and Metabolic Health at Hackensack University Medical Center for his advice.
From the Ozempic "ripple effect" to health tech and more, experts share their predictions for 2024 wellness trends.
The FDA and drugmaker Novo Nordisk are working to identify thousands of counterfeit Ozempic drugs seized in an ongoing investigation.
The medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.
